|
Market Closed -
Sao Paulo
15:54:30 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 63.78 BRL | -1.39% |
|
-6.36% | -10.05% |
| 10-02 | Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating | MT |
| 10-02 | Major drugmakers turn to China for licensing deals | RE |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66,029 | 77,057 | 93,403 | 76,639 | 79,193 | 73,413 | - | - |
| Change | - | 16.7% | 21.21% | -17.95% | 3.33% | -7.3% | - | - |
| Enterprise Value (EV) 1 | 56,196 | 77,057 | 84,542 | 70,331 | 73,294 | 65,991 | 63,098 | 59,539 |
| Change | - | 37.12% | 9.71% | -16.81% | 4.21% | -9.96% | -4.38% | -5.64% |
| P/E | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 16.8x | 14.5x | 12.7x |
| PBR | 3.56x | 3.41x | 3.64x | 2.62x | 2.58x | 2.23x | 1.95x | 1.71x |
| PEG | - | -0.4x | -2.8x | 1.8x | 2.27x | 2.9x | 0.9x | 0.9x |
| Capitalization / Revenue | 4.11x | 6.33x | 7.12x | 5.4x | 5.52x | 4.31x | 3.97x | 3.71x |
| EV / Revenue | 3.5x | 6.33x | 6.45x | 4.95x | 5.11x | 3.88x | 3.41x | 3.01x |
| EV / EBITDA | 5.71x | 12.7x | 15.2x | 12.3x | 13.5x | 9.16x | 7.93x | 6.58x |
| EV / EBIT | 6.28x | 13.5x | 16.5x | 13.5x | 15x | 10.6x | 8.84x | 7.49x |
| EV / FCF | 8.61x | 17.4x | 21.8x | 19.2x | 18x | 11.1x | 9.81x | 8.39x |
| FCF Yield | 11.6% | 5.74% | 4.58% | 5.21% | 5.57% | 8.98% | 10.2% | 11.9% |
| Dividend per Share 2 | - | - | - | - | 3.52 | 3.902 | 4.398 | 4.922 |
| Rate of return | - | - | - | - | 0.46% | 0.53% | 0.6% | 0.67% |
| EPS 2 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 43.88 | 50.63 | 57.81 |
| Distribution rate | - | - | - | - | 8.49% | 8.89% | 8.69% | 8.51% |
| Net sales 1 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | 17,014 | 18,511 | 19,787 |
| EBITDA 1 | 9,835 | 6,060 | 5,547 | 5,695 | 5,428 | 7,205 | 7,953 | 9,048 |
| EBIT 1 | 8,947 | 5,719 | 5,126 | 5,212 | 4,884 | 6,208 | 7,136 | 7,947 |
| Net income 1 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | 4,952 | 5,486 | 6,221 |
| Net Debt 1 | -9,833 | - | -8,862 | -6,308 | -5,899 | -7,422 | -10,316 | -13,875 |
| Reference price 2 | 631.52 | 721.49 | 878.29 | 712.33 | 771.87 | 735.20 | 735.20 | 735.20 |
| Nbr of stocks (in thousands) | 104,556 | 106,802 | 106,347 | 107,590 | 102,599 | 99,855 | - | - |
| Announcement Date | 2/4/22 | 2/3/23 | 2/2/24 | 2/4/25 | 1/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | |
| 28.48x | 6.32x | 17.74x | 2.09% | 617B | |
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | |
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | |
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | |
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | |
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | |
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | |
| Average | 26.61x | 6.52x | 17.28x | 2.29% | 410.8B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- REGN Stock
- REGN34 Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
